Key result
Fulminant myocarditis presents with sudden onset acute heart failure or cardiogenic shock, and its management is challenged by delayed recognition and a lack of standardized therapy guidelines.
This review summarizes the current literature on the recognition and recommended treatment for fulminant myocarditis, highlighting the need for standardized therapy guidelines.
Early subtype differentiation informs fulminant myocarditis prognosis; leaves open standardized immunosuppression for eosinophilic and giant-cell forms.
Myocarditis is an inflammatory disease of the myocardium with a wide spectrum of symptoms and severity. Fulminant myocarditis is a small cohort of this disease that tends to present with sudden onset acute heart failure, cardiogenic shock, or life-threatening arrhythmias. The most common type, and the one with the best likelihood for recovery, is lymphocytic myocarditis. More rare, and often more fatal, forms are eosinophilic myocarditis and giant cell myocarditis. Delayed recognition and lack of standardized therapy guidelines continue to challenge clinicians treating these critically ill patients. This article will review the most up-to-date literature regarding recognition and recommended treatment for fulminant myocarditis as it pertains to clinical practice.
No takes yet. Share an insight, caveat, or question.
Seif et al. (2018) conducted a review in Fulminant myocarditis. Fulminant myocarditis presents with sudden onset acute heart failure or cardiogenic shock, and its management is challenged by delayed recognition and a lack of standardized therapy guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: